Open AccessS159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT
Author(s) -
Busque L.,
Harnois M.,
Szuber N.,
Delage R.,
Mollica L.,
Olney H.,
Laneuville P.,
Sirhan S.,
Cournoyer G.,
Chamakhi I.,
Lalancette M.,
Talbot D.,
Éthier V.,
Desjardins P.,
Assouline S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843528.26169.66
Subject(s) - nilotinib , dasatinib , bosutinib , medicine , ponatinib , imatinib , chronic myelogenous leukemia , oncology , clinical trial , leukemia , myeloid leukemia